Cervical Cancer Disease Coverage Forecast and Market Analysis to 2023

  • ID: 4331625
  • Report
  • Region: Global
  • 69 pages
  • Datamonitor Healthcare
1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Bristol-Myers Squibb
  • Celgene
  • Genentech
  • GlaxoSmithKline
  • Merck KGaA
  • MORE
Cervical cancer is a major gynecological cancer which involves uncontrolled cell division and tissue invasiveness of the female uterine cervix. Incidence rates are highest in sub-Saharan Africa, Latin America and the Caribbean, and Oceania/Australasia, and lowest in Western Asia, Australia/New Zealand, and Northern America.

Human papillomavirus (HPV) is a major cause of the main types of cervical cancer (the two main histological subtypes being squamous cell cancer and adenocarcinoma), and is believed to be responsible for around 95% of cervical cancers.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Bristol-Myers Squibb
  • Celgene
  • Genentech
  • GlaxoSmithKline
  • Merck KGaA
  • MORE
Epidemiology: Cervical Cancer
  • Executive Summary
  • Disease Background
  • Sources and Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths and Limitations
Appendix
Appendix: Epidemiology: Cervical Cancer

List of Figures
Figure 1: Trends in incident cases of cervical cancer in the US, Japan, and five major EU markets, by country, 2016-36
Figure 2: Absolute change in incident cases of cervical cancer in the US, Japan, and five major EU markets, by country, 2016-36
Figure 3: Incident cervical cancer cases, by FIGO stage and country, 2016

List of Tables:
Table 1: Cervical cancer ICD-O-3 topography codes
Table 2: Cervical cancer staging, according to TNM and FIGO staging
Table 3: Cancer registry databases used as a source of cervical cancer incidence data, by country
Table 4: Forecasting methodology for cervical cancer incidence, by country and age group
Table 5: Data sources used to segment incident cervical cancer cases by FIGO stage, by country
Table 6: Data sources used to segment incident cervical cancer cases by histological subtype
Table 7: Incident cases of cervical cancer in the US, Japan, and five major EU markets, by country, 2016-36
Table 8: Age-specific incident cases of cervical cancer in the US, Japan, and five major EU markets, by country, 2016
Table 9: Proportion and number of incident cases of cervical cancer in the US, Japan, and five major EU markets, by FIGO stage and country, 2016
Table 10: Proportion and number of incident cases of cervical cancer in the US, Japan, and five major EU markets, by histological subtype and country, 2016
Table 11: Cervical screening programs and screening coverage, by country
Table 12: National HPV immunization programs in girls, by country
Table 13: Validation of cervical cancer forecast estimates against benchmark estimates, by country
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- AstraZeneca
- Bristol-Myers Squibb
- Celgene
- Genentech
- GlaxoSmithKline
- Merck KGaA
- Pfizer
- Roche
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll